Sepsis, August 2025 edition

This mechanistic study identifies homocysitaconate, generated through AHCY-catalyzed adduction of homocysteine and itaconate, as a potent anti-inflammatory metabolite. Homocysitaconate binds methionyl-tRNA synthetase, reshapes methionine metabolism, suppresses N-homocysteinylation, promotes NLRP3 ubiquitination, and improved outcomes in sepsis and other inflammatory models.

Impact: It reveals a previously unrecognized immunometabolic pathway directly connecting itaconate and homocysteine biology to inflammasome control, with therapeutic efficacy in sepsis models and multiple potential pharmacologic entry points.

Clinical Implications: The AHCY-MARS-methionine axis could support development of adjunctive anti-inflammatory therapy, but human pharmacokinetics, safety, target engagement, and appropriate treatment timing must be established before clinical translation.

This mechanistic study demonstrates that inflammatory phospholipid signaling activates cardiomyocyte HIF-1α, which suppresses mitochondrial respiration through iNOS-derived nitric oxide and causes cytopathic hypoxia and contractile dysfunction. Cardiac HIF-1α haploinsufficiency and pharmacologic inhibition of COX2 or sPLA2 attenuated mitochondrial and cardiac dysfunction.

Impact: It provides a coherent molecular link between inflammatory lipid metabolism, HIF-1α stabilization, mitochondrial failure, and septic cardiomyopathy, identifying several tractable intervention points for a major but under-targeted organ complication.

Clinical Implications: The COX2-sPLA2-PKA-iNOS/HIF-1α pathway merits testing in clinically relevant sepsis models, alongside development of lipid mediator and HIF-1α activity biomarkers to identify patients at risk for septic cardiomyopathy.

This translational study shows that Src activation drives NETosis in human and murine neutrophils and is associated with prognosis in acute pancreatitis and sepsis. Genetic deletion or pharmacologic inhibition of Src reduced NET formation and ROS through RAF/MEK/ERK signaling, thereby limiting organ injury in vivo.

Impact: The study identifies a druggable kinase that regulates NETosis through a defined signaling cascade and links its inhibition to reduced organ injury, creating a plausible translational path for NET-driven sepsis phenotypes.

Clinical Implications: Src inhibitors may be evaluated as adjunctive therapies for NET-driven organ injury, with phosphorylated Src and NET markers serving as pharmacodynamic indicators; immunosuppression and infection-control risks require careful assessment.

This preclinical study shows that endothelial-derived CCL7 activates CCR1-positive macrophages, promotes metabolic reprogramming and M1 polarization through KAT2A-dependent STAT1 succinylation, and aggravates septic acute lung injury. Endothelial-specific CCL7 inhibition reduced lung injury severity in murine sepsis models.

Impact: It defines a novel endothelial-macrophage epigenetic-metabolic axis that causally links vascular signaling to inflammatory lung injury and offers multiple druggable nodes.

Clinical Implications: CCR1 antagonists, KAT2A modulators, or strategies that reduce endothelial CCL7 release warrant testing in translational models, together with human validation of endothelial and macrophage signatures.

This Cochrane review of four randomized trials involving 42,846 participants found that single-dose intrapartum antibiotic prophylaxis, predominantly azithromycin, probably reduces maternal sepsis without clear effects on neonatal sepsis or mortality. Short-term increases in antimicrobial resistance were observed, while persistent differences at 11 to 13 months were not demonstrated.

Impact: This is high-level evidence with direct policy relevance for maternal sepsis prevention, while explicitly addressing the trade-off between reduced maternal infection and antimicrobial resistance.

Clinical Implications: Single-dose intrapartum prophylaxis may be considered in appropriate settings, accompanied by antimicrobial stewardship, resistance surveillance, and local assessment of baseline maternal sepsis risk and pathogen epidemiology.